Evidence map›Paper›PMID 33037392›Full record

ArticleJournal of human genetics2021

The third case of TNFRSF11A-associated dysosteosclerosis with a mutation producing elongating proteins.

Jing-Yi Xue, Zheng Wang, Sarah F Smithson, Christine P Burren, Naomichi Matsumoto, Gen Nishimura, Shiro Ikegawa, Long Guo

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. A Null Mutation ofFrontiers in genetics · 2022
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Jing-Yi XueLaboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
Zheng WangLaboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
Sarah F SmithsonBristol Medical School Translational Health Sciences, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-5575-0357
Christine P BurrenBristol Medical School Translational Health Sciences, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-3778-2945
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9846-6500
Gen NishimuraLaboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
Shiro IkegawaLaboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan. sikegawa@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-0316-2147
Long GuoLaboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan. longguo601@gmail.com.ORCID http://orcid.org/0000-0002-9660-6941
RIKEN Center for Integrative Medical Sciences · JPUniversity Hospitals Bristol NHS Foundation Trust · GBChinese Academy of Medical Sciences & Peking Union Medical College · CNYokohama City University · JP

Funding

Japan Agency for Medical Research and Development (AMED) 20bm0804006h0104Japan Agency for Medical Research and Development (AMED) 20ek0109486h0001Japan Agency for Medical Research and Development (AMED) JP20ek0109301Japan Agency for Medical Research and Development (AMED) JP20ek0109348Japan Agency for Medical Research and Development (AMED) JP20ek0109486Japan Agency for Medical Research and Development (AMED) JP20kk0205012MEXT | Japan Society for the Promotion of Science (JSPS) 18H02932
6 · The paper itself

Abstract

Dysosteosclerosis (DOS) is a distinct form of sclerosing bone disease characterized by platyspondyly and progressive osteosclerosis. DOS is genetically heterogeneous. Three causal genes, SLC29A3, CSF1R, and TNFRSF11A are reported. TNFRSF11A-associated DOS has been identified in two patients; however, TNFRSF11A is also a causal gene for osteopetrosis, autosomal recessive 7 (OP-AR7). Whole-exome sequencing in a patient with sclerosing bone disease identified novel compound heterozygous variants (c.414_427 + 7del, c.1664del) in TNFRSF11A. We examined the impact of the two variants on five splicing isoforms of TNFRSF11A by RT-PCR. We found that c.1664del resulted in elongated proteins (p.S555Cfs*121, etc.), while c.414_427 + 7del generated two aberrant splicing products (p.A139Wfs*19 and p.E132Dfs*19) that lead to nonsense mediated mRNA decay (NMD). In the previous two cases of TNFRSF11A-associated DOS, their mutations produced truncated TNFRSF11A protein isoforms. The mutations in all three cases thus contrast with TNFRSF11A mutations reported in OP-AR7, which does not generated truncated or elongated TNFRSF11A proteins. Thus, we identified the third case of TNFRSF11A-associated DOS and reinforced the genotype-phenotype correlation that aberrant protein-producing TNFRSF11A mutations cause DOS.

Indexed as

MutationChild, PreschoolExome SequencingFemaleHumansOsteosclerosisPrognosisReceptor Activator of Nuclear Factor-kappa BReceptor Activator of Nuclear Factor-kappa BTNFRSF11A protein, human

Identifiers

PMID33037392
OpenAlexW3091879665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.